Robert Khederian, chairman of the board of Cambridge Heart (Bedford, Massachusetts), has been named interim president/CEO of the company. The appointment comes following the resignation of Jeffery Langan as president/CEO, and a member of the board. Khederian is a majority shareholder and has served as a director of the company since 2002. In addition, Ali Haghighi-Mood, PhD has been promoted to serve as executive VP and COO, and Laurence Blumberg, MD, a member of the board, has been appointed to serve as VP of business development. Cambridge Heart develops products for the non-invasive diagnosis of cardiac disease, particularly the identification of at-risk sudden cardiac arrest.

No Comments